Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

SHANGHAI (Reuters) -The Beijing-based American Chamber of Commerce said on Friday that companies in the pharmaceutical sector ...

Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on ...

Shares of SpringWorks Therapeutics (NASDAQ:SWTX) reached a session high on Thursday after The Wall Street Journal reported ...

Futures trade pointed to a higher open on European stock markets, adding to a second straight weekly gain as the shock wears ...

After an early wobble, markets resumed rising after Chinese officials contradicted suggestions from President Trump and ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

Shares of Merck and Verizon are retreating Friday morning, sending the Dow Jones Industrial Average into negative territory.

Germany’s Merck KGaA (DE:MRK) is in advanced talks to buy U.S.-based SpringWorks Therapeutics (SWTX) for roughly $3.5 billion, aiming to boost ...